27 Dec 2021
Bristol-Myers Squibb Co: Opdivo, Revlimid, and Eliquis Continue To Drive Growth (12/2021)
Bristol-Myers Squibb had a robust third quarter, with significant sales growth fueled by strong commercial execution and pipeline advancement. They performed well in their commercial units which drove demand growth for their launch products and delivered a strong performance of their In-Line products, including Opdivo, Revlimid, and Eliquis. In the third quarter, the company advanced its third I-O mechanism with the fixed dose of Relatlimab plus Nivolumab approved for priority review in the U.S. ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Bristol-Myers Squibb Co: Opdivo, Revlimid, and Eliquis Continue To Drive Growth (12/2021)
Bristol-Myers Squibb Company (BMY:NYS) | 0 0 0.0%
- Published:
27 Dec 2021 -
Author:
Ishan Majumdar -
Pages:
14
Bristol-Myers Squibb had a robust third quarter, with significant sales growth fueled by strong commercial execution and pipeline advancement. They performed well in their commercial units which drove demand growth for their launch products and delivered a strong performance of their In-Line products, including Opdivo, Revlimid, and Eliquis. In the third quarter, the company advanced its third I-O mechanism with the fixed dose of Relatlimab plus Nivolumab approved for priority review in the U.S. ....